Lyn Barinowski

Chief Executive Officer

I am a high-impact biopharmaceutical industry executive with more than 20 years of experience. In my current role as CEO of Avalyn Pharma, I am working with a talented team to build and grow a respiratory-focused company with a lead asset for IPF & ILD advancing through clinical development. I also serve on the Board of Rani Therapeutics (NASDAQ: RANI). I have led a vast array of functions in biotech, big pharma, and venture capital firms with a focus in the respiratory therapeutic area. Prior to joining Avalyn, I served as chief operating officer at Altavant Sciences, a biopharmaceutical company that successfully built and developed a portfolio of therapies for rare respiratory diseases prior to its 2019 acquisition by Sumitomo Dainippon. Earlier in my career, I served in senior-level corporate development and commercial roles, including vice president of commercial development at Pearl Therapeutics, which successfully developed a portfolio of asthma & COPD medicines prior to its sale to AstraZeneca for $1.15 Billion in 2013; and vice president in a healthcare-focused venture capital firm based in New York. I previously held roles in business development, marketing and public affairs with Novartis Pharmaceuticals in Switzerland and the U.S.

Talks About
#biopharmaceuticals #privateequity

Preferred Locations
#NorthAmerica